QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)
QQQ   432.79 (+0.19%)
AAPL   188.32 (-0.58%)
MSFT   414.11 (+0.01%)
META   470.00 (+0.09%)
GOOGL   145.91 (+0.25%)
AMZN   169.84 (-0.40%)
TSLA   189.56 (+1.06%)
NVDA   696.41 (-0.65%)
NIO   5.82 (-0.68%)
AMD   169.35 (-0.93%)
BABA   70.74 (-3.94%)
T   16.82 (-2.94%)
F   12.83 (+0.23%)
MU   84.88 (-0.34%)
CGC   4.11 (-4.86%)
GE   139.07 (+0.41%)
DIS   110.54 (+11.50%)
AMC   4.09 (+3.81%)
PFE   27.56 (+0.00%)
PYPL   56.13 (-11.24%)
XOM   103.97 (+1.71%)

Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target

→ Critical asset just had biggest fall on record (From Stansberry Research) (Ad)
Free ARWR Stock Alerts
$30.85
-0.80 (-2.53%)
(As of 02/8/2024 ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Arrowhead Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 13 Analyst Ratings

Analysts' Consensus Price Target

$51.25
66.13% Upside
High Forecast$90.00
Average Forecast$51.25
Low Forecast$27.00
TypeCurrent Forecast
2/8/23 to 2/8/24		1 Month Ago
1/9/23 to 1/9/24		3 Months Ago
11/10/22 to 11/10/23		1 Year Ago
2/8/22 to 2/8/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
10 Buy rating(s)
11 Buy rating(s)
8 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
5 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$51.25$51.77$54.53$60.10
Predicted Upside66.13% Upside69.86% Upside78.44% Upside92.00% Upside
Get Arrowhead Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.

ARWR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ARWR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Arrowhead Pharmaceuticals Stock vs. The Competition

TypeArrowhead PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.62
2.67
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside62.39% Upside920.74% Upside9.25% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/8/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$90.00+184.00%
2/7/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetEqual Weight ➝ Equal Weight$34.00 ➝ $36.00+13.74%
2/7/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral ➝ Neutral$33.00 ➝ $34.00+6.92%
2/7/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform ➝ Outperform$50.00+60.41%
1/2/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$29.00 ➝ $37.00+17.61%
8/8/2023Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$60.00+121.32%
8/8/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		P. Agrawal
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOverweight ➝ Overweight$79.00 ➝ $47.00+69.98%
7/21/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform
7/20/2023B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$55.00+58.00%
6/2/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$52.00 ➝ $59.00+70.18%
5/12/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. Foroohar
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Market Perform
5/12/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform$40.00-0.20%
5/3/2023500.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingReiterates
4/26/2023Sumitomo Mitsui Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageOutperform$80.00+138.24%
3/21/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageMarket Perform$27.00+7.74%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:49 PM ET.












ARWR Price Target - Frequently Asked Questions

What is Arrowhead Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 13 analysts in the last year, the consensus rating for Arrowhead Pharmaceuticals stock is Moderate Buy based on the current 5 hold ratings and 8 buy ratings for ARWR. The average twelve-month price prediction for Arrowhead Pharmaceuticals is $51.25 with a high price target of $90.00 and a low price target of $27.00. Learn more on ARWR's analyst rating history.

Do Wall Street analysts like Arrowhead Pharmaceuticals more than its competitors?

Analysts like Arrowhead Pharmaceuticals less than other Medical companies. The consensus rating score for Arrowhead Pharmaceuticals is 2.62 while the average consensus rating score for medical companies is 2.67. Learn more on how ARWR compares to other companies.

Does Arrowhead Pharmaceuticals's stock price have much upside?

According to analysts, Arrowhead Pharmaceuticals's stock has a predicted upside of 62.19% based on their 12-month stock forecasts.

What analysts cover Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals has been rated by Bank of America, Citigroup, HC Wainwright, Morgan Stanley, and Royal Bank of Canada in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:ARWR) was last updated on 2/8/2024 by MarketBeat.com Staff

From Our Partners
Billionaires Are Now FLOODING Into Gold
Stansberry Research
A Weird Income Tactic So Simple and So Lucrative...
The Oxford Club
The Elites Are Waging War on Elon Musk — Here's Why…
Porter and Company
All the trading advice you’ve ever received boils down to this
DTI
Clear Buy, Sell, or Hold Recommendation on any Stock, FREE
Vector Vest
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse
Legacy Research
Laser breakthrough could send stock soaring 2,467%
Behind the Markets
Stop buying AI stocks!
Investor Place Media
pixel

My Account -